Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer von Mansfield, A.S., Aubry, M.C., Moser, J.C., Harrington, S.M., Dronca, R.S., Park, S.S., Dong, H.

Volltext

Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer von Fuentes, H.E, Oramas, D.M, Paz, L.H, Casanegra, A.I, Mansfield, A.S, Tafur, A.J

Volltext

115 Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer von Mansfield, A.S, Tafur, A.J, Kourelis, T.V, Wysokinska, E.M, Yang, P

Volltext

Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis von Tafur, A.J, Dale, G, Cherry, M, Wren, J.D, Mansfield, A.S, Comp, P, Rathbun, S, Stoner, J.A

Volltext

70 Heterogeneity of programmed death-ligand 1 expression in multifocal lung cancer von Mansfield, A.S, Murphy, S, Peikert, T, Yi, J, Vasmatzis, G, Wigle, D, Aubry, M.C

Volltext

Early Venous Thromboembolic Events Are Associated With Worse Prognosis in Patients With Lung Cancer von Kourelis, T, Wysokinska, E.M, Wang, Y, Yang, P, Tafur, A.J, Mansfield, A.S

Volltext

Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials von Mansfield, A.S, Tafur, A.J, Vulih, D, Smith, G.L, Harris, P.J, Ivy, S.P

Volltext

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 von Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M.A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A.K., Fujimoto, N., Tsao, A.S., Mansfield, A.S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., Zalcman, G.

Volltext

EP08.02-037 Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib von Dimou, A., Lo, Y.-C., Halling, K., Mansfield, A.S.

Volltext

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial von Mansfield, A.S., Każarnowicz, A., Karaseva, N., Sánchez, A., De Boer, R., Andric, Z., Reck, M., Atagi, S., Lee, J.-S., Garassino, M., Liu, S.V., Horn, L., Wen, X., Quach, C., Yu, W., Kabbinavar, F., Lam, S., Morris, S., Califano, R.

Volltext

Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer von Mansfield, A. S., Tafur, A. J., Wang, C. E., Kourelis, T. V., Wysokinska, E. M., Yang, P.

Volltext

84MO Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups von Asmann, Y., Parikh, K., Borad, M., Bergsagel, L., Mansfield, A.S.

Volltext

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial von Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C.S., Tan, D.S.W., Lee, D.H., Misch, D., Garralda, E., Kim, D.-W., van der Wekken, A.J., Gainor, J.F., Paz-Ares, L., Liu, S.V., Kalemkerian, G.P., Houvras, Y., Bowles, D.W., Mansfield, A.S., Lin, J.J., Smoljanovic, V., Rahman, A., Kong, S., Zalutskaya, A., Louie-Gao, M., Boral, A.L., Mazières, J.

Volltext

Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas von Majithia, N., Aubry, M.C., Murphy, S., Mansfield, A.S.

Volltext

17P Effects of tumour mutation burden on the antigen presentation pathway von Garcia-Rivera, E.M., Park, J., Truntzer, C., Ghiringhelli, F., Mansfield, A.S.

Volltext

P3.12C.01 BRAF Mutation Diversity and Impact on Clinical Outcomes in Non-Small Cell Lung Cancer von Lu, K., Shen, J.P., Lopez-Diaz, F.J., Leal, A., Woodward, B.D., Velcheti, V., Riess, J.W., Mansfield, A.S., Salgia, R., Husain, H.

Volltext

1026MO Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours von Karp, D.D., Dronca, R.S., Camidge, R., Costello, B.A., Mansfield, A.S., Ames, T.D., Jimeno, J.M., Bryce, A.H.

Volltext

1230P Association between early endpoints and survival outcomes in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC): A multi-country retrospective study von Provencio Pulla, M., Berry, L., Quintana, M., LeBlanc, T.W., Mascaux, C., Schabath, M., Bestvina, C.M., Tratt, M., Mansfield, A.S., Bates, M., Gentzler, R.D., Girard, N., Couraud, S., Tan, C.J., Wislez, M., Wei, B., Calvet, C., Berry, D.A., Vo, L., Stenehjem, D.

Volltext

EP11.03-26 Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression von Parikh, K., Leventakos, K., Mansfield, A.S., Dimou, A., Molina, J.R., Ambrose, J., Bai, C., Hansen, E., Barcellos, A., Zettler, C., Belli, A., Fernandes, L., Wang, C.-K.

Volltext

EP14.04-01 BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma von Smith, C.J., Desai, A., Hazim, A., Dimou, A., Leventakos, K., Molina, J., Parikh, K., Kommalapati, A., Hocum, C., Moffett, J.N., Schwecke, A., Mansfield, A.S.

Volltext